Tafamidis is a medication used to treat transthyretin-mediated amyloidosis. Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX.
- Mechanism
- Curator reviewed · 5 references
Genetic mutations or natural misfolding of transthyretin destabalizes transthyretin tetramers, leading to their dissociation and aggregation in tissues, and disrupting the normal function of these tissues. Tafamidis binds to transthyretin tetramers at the thyroxin binding sites, stabilizing the tetramer, reducing the availability of monomers for amyloidogenesis.
- Primary indication
- Tafamidis is indicated to treat cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults.Curator reviewed · 1 structured indication
- Formula / weight
- C14H7Cl2NO3 · 308.116 g/mol (avg)
- First approval
- Canada, 2020 · United States, 2019 · European Union, 2016
- Also known as
- 2-(3,5-Dichlorophenyl)benzoxazole-6-carboxylic acid · 6-BENZOXAZOLECARBOXYLIC ACID, 2-(3,5-DICHLOROPHENYL)-
- Code names
- FX-006 · FX-1005 · FX-1006
- Brand names
Resolves to
TXEIIPDJKFWEEC-UHFFFAOYSA-NSMILESOC(=O)C1=CC=C2N=C(OC2=C1)C1=CC(Cl)=CC(Cl)=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Tafamidis, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account